Sangamo Therapeutics (SGMOQ) EBT Margin (2010 - 2025)

Sangamo Therapeutics' EBT Margin history runs 16 years deep, the most recent figure standing at 266.88% for Q4 2025.

• On a quarterly basis, EBT Margin rose 9963.0% year-over-year to 266.88% in Q4 2025; TTM through Dec 2025 was 312.25%, a 13937.0% decrease from a year earlier, with the FY2025 full-year figure at 312.25%, down 14251.0% from the prior year.
• EBT Margin grew to 266.88% in Q4 2025 per SGMOQ's latest filing, from 6039.76% in the prior quarter.
• Across five years, EBT Margin topped out at 21.78% in Q3 2024 and bottomed at 10185.24% in Q1 2024.
• The 5-year median for EBT Margin is 195.35% (2022), against an average of 1734.89%.
• Across the five-year window, EBT Margin slumped 1019874 bps in 2024 and jumped 1001850 bps in 2025, its largest moves.
• Year by year, EBT Margin stood at 134.22% in 2021, then sank by 41 bps to 189.92% in 2022, then slumped by 1462 bps to 2966.06% in 2023, then soared by 88 bps to 366.51% in 2024, then advanced by 27 bps to 266.88% in 2025.
• Per Business Quant, the three latest SGMOQ EBT Margin figures stand at 266.88% (Q4 2025), 6039.76% (Q3 2025), and 109.03% (Q2 2025).